- Home
- ZTEK vs CALC Comparison
ZTEK vs CALC Comparison
Compare ZTEK & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZTEK | CALC |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8M | 88.3M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ZTEK | CALC |
|---|---|---|
| Price | $0.61 | $0.80 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 123.6K | ★ 476.8K |
| Earning Date | 02-18-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $0.46 |
| 52 Week High | $1.84 | $7.20 |
Technical Indicators
Market Signals| Indicator | ZTEK | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 42.10 | 37.42 |
| Support Level | $0.55 | $0.49 |
| Resistance Level | $0.67 | $0.79 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | 0.00 | 0.14 |
| Stochastic Oscillator | 53.85 | 68.17 |
Price Performance
Historical ComparisonAbout ZTEK Zentek Ltd.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.